Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning ways. At its Capital Markets Day on 21 September, Novo's strategy was headlined by an ambition to launch more than five multi-blockbusters by 2030. This is accompanied by a target to deliver more than DKr150bn ($23bn) in sales. The moves are part of Novo's strategy to showcase to investors what its roadmap looks like beyond semaglutide. The injectable versions of the drug, branded under Wegovy and Ozempic, generated around $7.8bn in global sales in Q2. However, the company is lagging Eli Lilly in the cardiometabolic space.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.